⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
TB-500 (Thymosin Beta-4) (Nasal Spray)
TB-500 (Thymosin Beta-4) in nasal form is being researched for potential neuroprotective effects. Data is primarily from animal models.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Mechanism of Action
TB-500 (Thymosin Beta-4) regulates the G-actin/F-actin transformation, promoting cell migration and tissue repair. Via nasal administration, it may theoretically provide central access for neuroprotection. Animal studies in TBI show a reduction in inflammation and improved neurogenesis.
Overview
- Investigational stage — no approved nasal formulation exists
- Medium molecular weight (~4.9 kDa)
- Research dosing: ~250–750 mcg per application
- No self-compounding instructions are provided
Intranasal Delivery — Research Data
- Nasal administration of TB-500 (Thymosin Beta-4) is in the investigational stage.
- TB-500 is a 43-amino acid peptide (~4.9 kDa) — a medium size that theoretically allows for some nasal absorption.
- Animal data suggest neuroprotective properties after traumatic brain injury.
Investigational
The intranasal form is at an investigational stage. Available data is limited.
Dosing Table — TB-500 Nasal Spray (Investigational)
| Period | Dose | Notes |
|---|---|---|
| Investigational dose | 250–750 mcg × 1–2/day | Per formulation |
Research data. There is no established nasal dosage in humans.
Formulation Notes
No self-preparation instructions provided
- No approved nasal formulation exists.
- Self-compounding of a nasal spray is not recommended.
Storage After Opening
- Refrigerator (2–8°C) after opening.
- Use within 14 days.
Dosing Protocol
- Research dosing: 250–750 mcg per nostril.
- Frequency: 1–2 times daily.
Storage Instructions
- Refrigerator (2–8°C).
- Protect from light.
Important Notes
- Not approved by the FDA or EMA in any form.
- Data on nasal administration are preclinical (animal models).
- The subcutaneous form remains the most studied route.
- No self-compounding instructions are provided.
Benefits & Side Effects
Potential Benefits
- Theoretical neuroprotection after TBI (animal data)
- Non-invasive administration
- Anti-inflammatory properties (research data)
Potential Side Effects
- Mild nasal irritation (possible)
- Insufficient safety data for the nasal form in humans
References
Intranasal Peptide Delivery: Complete Guide
Bioavailability, absorption factors, comparison with injectables, and limitations of nasal delivery.
Research Limitations
The data on this page is strictly educational. No self-preparation or self-administration instructions are provided.
External Sources & Regulatory Status
Regulatory Approvals
Research-only — No regulatory approval
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →